Nuclear Fusion Pioneer Raises £23m to Battle Cancer

Astral Systems raises £23m to scale its nuclear fusion technology

Bristol-based deep tech firm Astral Systems has secured a £23m Series A round led by Mercia Ventures.  Astral Systems has created and commercialised a multi-state fusion technology – a new type of nuclear fusion that could tackle the fragile supply chain and potential global shortages of medical radioisotopes that impact cancer diagnosis and treatments. With the Series A capital and its new facility being developed at the former Berkeley Power S…

Nuclear fusion start-up pioneering tech to help treat cancer secures £23m

The company is a developing a new high-energy facility at the former Berkeley Power Station in Gloucestershire

Nuclear fusion pioneer raises £23m to battle cancer

Astral Systems – a deep-tech firm pioneering a new type of nuclear fusion technology – has secured £23 million in the first close of a Series A investment led by Mercia Ventures.  The round is supported by prominent tech investors including Tees River, Daphni and Blast Club, alongside previous investors Speedinvest and Playfair Capital. It will enable the company to use its proprietary multi-state fusion (MSF) technology to develop medical isoto…

Fusion pioneer powers ahead with backing

A Bristol-based deep-tech company has raised £23 million to develop nuclear fusion technology aimed at tackling shortages of medical isotopes used in cancer diagnosis and treatment. Astral Systems has secured the first close of a Series A investment round led by Mercia Ventures, with backing from Tees River, Daphni, Blast Club…

Bristol fusion startup raises £23M to produce cancer-fighting isotopes while the rest of the industry is still 20 years away

Bristol fusion startup Astral Systems has closed a £23M Series A led by Mercia Ventures to scale production of medical isotopes critical to cancer diagnosis and treatment. Unlike most fusion companies that are still building toward long-term power generation, Astral already operates reactors and has generated more than £3M in revenue from research contracts. More than 50 million nuclear medicine procedures a year depend on a global isotope suppl…